Can pulmonary artery hypertension be attributed to levosimendan? A problematic based on a patient's case.
Tagarakis
Georgios I
GI
Baddour
Andony J
AJ
Tsilimingas
Nikolaos B
NB
D000368:Aged; D001024:Aortic Valve Stenosis / Q000150:complications / Q000601:surgery; D001794:Blood Pressure / Q000187:drug effects*; D002316:Cardiotonic Agents / Q000008:administration & dosage / Q000009:adverse effects*; D001026:Coronary Artery Bypass; D003324:Coronary Artery Disease / Q000150:complications / Q000601:surgery; D019918:Heart Valve Prosthesis Implantation; D006801:Humans; D006835:Hydrazones / Q000008:administration & dosage / Q000009:adverse effects*; D006976:Hypertension, Pulmonary / Q000139:chemically induced* / Q000503:physiopathology; D011651:Pulmonary Artery / Q000187:drug effects* / Q000503:physiopathology; D011724:Pyridazines / Q000008:administration & dosage / Q000009:adverse effects*; D000077464:Simendan
D002316:Cardiotonic Agents; D006835:Hydrazones; D011724:Pyridazines; D000077464:Simendan